Figure 1.
Treatment of patients with CAR immune cells. In the first step, immune cells are isolated from the patient’s blood by leukapheresis. These autologous immune cells are then manufactured off-site and genetically modified to target and kill antigen carrying cancer cells. The treatment is initiated by intravenous infusion of CAR immune cells into the patient.
